{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:05:44Z","timestamp":1781247944579,"version":"3.54.1"},"reference-count":56,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/14737140.2025.2587295","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T23:20:49Z","timestamp":1762816849000},"page":"307-320","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-4325","authenticated-orcid":false,"given":"Kevin G.","family":"Keane","sequence":"first","affiliation":[{"name":"University of Western Australia","place":["Perth, Australia"]},{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","place":["Camperdown, Australia"]},{"name":"South Metropolitan Health Service","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Redfern","sequence":"additional","affiliation":[{"name":"University of Western Australia","place":["Perth, Australia"]},{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","place":["Camperdown, Australia"]},{"name":"South Metropolitan Health Service","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Lim","sequence":"additional","affiliation":[{"name":"University of Western Australia","place":["Perth, Australia"]},{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","place":["Camperdown, Australia"]},{"name":"South Metropolitan Health Service","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickon","family":"Hayne","sequence":"additional","affiliation":[{"name":"University of Western Australia","place":["Perth, Australia"]},{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","place":["Camperdown, Australia"]},{"name":"South Metropolitan Health Service","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01350-9"},{"key":"e_1_3_5_3_1","volume-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drug and biological products for treatment, guidance for industry","author":"Food and Drug Administration (FDA)","year":"2024","unstructured":"Food and Drug Administration (FDA). BCG-unresponsive nonmuscle invasive bladder cancer: developing drug and biological products for treatment, guidance for industry. 2024. https:\/\/www.fda.gov\/media\/101468\/download"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612596"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6498-2"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00178-5"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03716-3"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.02.010"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.08.004"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03025-3"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.017"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001008640.01272.9d.20"},{"key":"e_1_3_5_16_1","unstructured":"Durvalumab and vicineum in subjects with high-grade non-muscle-invasive bladder cancer previously treated with bacillus Calmette-Guerin (BCG). ClinicalTrials.gov ID NCT03258593. 2021."},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16325"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.12.018"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0354"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.004"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.01.013"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.595"},{"key":"e_1_3_5_23_1","unstructured":"Phase Ib study of Avelumab plus Bacille Calmette-Guerin (BCG) in patients with non-muscle invasive bladder cancer (ABC trial) [Internet]. 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03892642"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-1683(24)01119-4"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03894-2"},{"key":"e_1_3_5_26_1","unstructured":"A study comparing the efficacy and safety of nivolumab in combination with bacillus Calmette-guerin (BCG) versus BCG alone in participants with high-risk non-muscle invasive bladder cancer (hr NMIBC) (CheckMate 7G8) (NCT04149574) [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04149574"},{"key":"e_1_3_5_27_1","unstructured":"A study of nivolumab or nivolumab plus experimental medication BMS-986205 with or without bacillus Calumette-Guerin (BCG) in BCG unresponsive bladder cancer that has not invaded into the muscle wall of the bladder (CheckMate 9UT) (NCT03519256) [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03519256"},{"key":"e_1_3_5_28_1","unstructured":"Phase ii study of pembrolizumab (MK-3475) and Bacillus Calmette-Gu\u00e9rin (BCG) as first-line treatment for high-risk T1 non-muscle-invasive bladder cancer (NMIBC) and high-grade non-muscle-invasive upper tract urothelial cell carcinoma (NMI-UTUCC) [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03504163"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS722"},{"key":"e_1_3_5_30_1","unstructured":"Testing the addition of an anti-cancer drug pembrolizumab to the usual intravesical chemotherapy treatment (gemcitabine) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NCT04164082). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04164082"},{"key":"e_1_3_5_31_1","unstructured":"IDO and PD-L1 peptide based immune-modulatory therapeutic (IO102-IO103) in combination with pembrolizumab for BCG-unresponsive or intolerant non-muscle invasive bladder cancer Available from: https:\/\/clinicaltrials.gov\/study\/NCT05843448"},{"key":"e_1_3_5_32_1","unstructured":"A phase III randomized open-label multi-center global study of durvalumab and bacillus Calmette-Guerin (BCG) administered as combination therapy versus BCG alone in high-risk BCG na\u00efve non-muscle invasive bladder cancer patients [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03528694"},{"key":"e_1_3_5_33_1","unstructured":"BCG in combination with durvalumab in adult BCG-na\u00efve high-risk NMIBC participants (PATAPSCO) (NCT05943106) [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05943106"},{"key":"e_1_3_5_34_1","unstructured":"Durvalumab in combination with S-488210\/S-488211 vaccine in non-muscle invasive bladder cancer (durance) Available from: https:\/\/clinicaltrials.gov\/study\/NCT04106115"},{"key":"e_1_3_5_35_1","unstructured":"Modern immunotherapy in BCG-unresponsive BCG-relapsing and high risk BCG-naive non-muscle invasive urothelial carcinoma of the bladder (ADAPT-BLADDER) Available from: https:\/\/clinicaltrials.gov\/study\/NCT03317158#study-overview"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS903"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4589"},{"key":"e_1_3_5_38_1","unstructured":"Bladder preservation by radiotherapy and immunotherapy in BCG unresponsive non-muscle invasive bladder cancer (prevert) (NCT03950362) [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03950362"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(24)01168-0"},{"key":"e_1_3_5_40_1","unstructured":"Safety and efficacy study of Tislelizumab in combination with BCG in HR-NMIBC patients (TACBIN-01) (TACBIN-01) [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04922047"},{"key":"e_1_3_5_41_1","unstructured":"Disitamab vedotin combined with Tislelizumab for HER2 overexpressing high-risk non-muscle-invasive urothelial bladder carcinoma which is not completely resectable. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05495724"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3321"},{"key":"e_1_3_5_43_1","unstructured":"Safety and efficacy of BCG combined with Tislelizumab for BCG-untreated patients with high-risk non-muscle invasive bladder cancer Available from: https:\/\/clinicaltrials.gov\/study\/NCT05580354"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4594"},{"key":"e_1_3_5_45_1","unstructured":"Study of HX008 for the treatment of BCG-unresponsive non-muscle invasive bladder cancer Available from: https:\/\/clinicaltrials.gov\/study\/NCT04738630"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0817"},{"key":"e_1_3_5_48_1","unstructured":"Study of CG0070 given in combination with pembrolizumab in non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin (CORE-001). NCT04387461. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04387461"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.293"},{"key":"e_1_3_5_50_1","unstructured":"Durvalumab and vicineum in subjects with high-grade non-muscle-invasive bladder cancer previously treated with bacillus Calmette-Guerin (BCG) (NCT03258593). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03258593"},{"key":"e_1_3_5_51_1","unstructured":"UroToday. AUA 2021: interim analysis of a phase I single-arm study of the combination of durvalumab and vicineum in subjects with high-grade NMIBC previously treated with BCG 2021. Available from: https:\/\/www.urotoday.com\/conference-highlights\/aua-2021-program\/aua-2021-bladder-cancer\/131953-aua-2021-interim-analysis-of-a-phase-i-single-arm-study-of-the-combination-of-durvalumab-and-vicineum-in-subjects-with-high-grade-nmibc-previously-treated-with-bcg.html#:~:text=Five%20patients%20(42%25)%20were be%20helpful%20in%20predicting%20responders"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2375-7"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"e_1_3_5_54_1","unstructured":"Ferlay JE Lam F Laversanne M et al. Global cancer observatory: cancer today. 2024."},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16332"},{"key":"e_1_3_5_56_1","unstructured":"A randomized phase III trial of intravesical BCG versus intravesical docetaxel and gemcitabine treatment in BCG na\u00efve high grade non-muscle invasive bladder cancer (BRIDGE) [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05538663"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4504"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2587295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:46:01Z","timestamp":1772765161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2587295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/14737140.2025.2587295"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2587295","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}